Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
The new centre brings advanced corneal procedures pioneered in India
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
Subscribe To Our Newsletter & Stay Updated
